Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Trimmed by Opes Wealth Management LLC

Opes Wealth Management LLC decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 157,976 shares of the biopharmaceutical company’s stock after selling 277 shares during the period. Gilead Sciences makes up 3.1% of Opes Wealth Management LLC’s portfolio, making the stock its 5th largest position. Opes Wealth Management LLC’s holdings in Gilead Sciences were worth $12,798,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Altfest L J & Co. Inc. bought a new stake in Gilead Sciences in the fourth quarter worth about $210,000. Federated Hermes Inc. raised its position in Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after acquiring an additional 175,925 shares during the period. Abundance Wealth Counselors bought a new stake in Gilead Sciences in the third quarter worth about $1,881,000. Toronto Dominion Bank raised its position in Gilead Sciences by 66.6% in the third quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company’s stock worth $96,589,000 after acquiring an additional 515,191 shares during the period. Finally, Mackenzie Financial Corp raised its position in Gilead Sciences by 8.9% in the fourth quarter. Mackenzie Financial Corp now owns 535,557 shares of the biopharmaceutical company’s stock worth $43,385,000 after acquiring an additional 43,630 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on GILD shares. Barclays lowered their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Cantor Fitzgerald lowered their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 26th. Mizuho lowered their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Finally, Wells Fargo & Company lowered their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $84.71.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $0.77 during midday trading on Thursday, reaching $66.16. 6,440,752 shares of the stock were exchanged, compared to its average volume of 7,307,979. The company’s fifty day moving average is $72.25 and its 200-day moving average is $76.66. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The firm has a market cap of $82.37 billion, a PE ratio of 14.87, a PEG ratio of 0.92 and a beta of 0.19. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period last year, the company posted $1.67 EPS. The business’s revenue was down 3.7% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.66%. The ex-dividend date was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is currently 68.44%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.